Starling Oncology (STLNW) Net Income towards Common Stockholders (2020 - 2026)

Starling Oncology (STLNW) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 41.1% year-over-year to -$8.2 million; the trailing twelve-month figure through Jun 2026 stood at -$30.5 million (up 43.58% YoY), and the FY2025 full-year result was -$50.3 million, up 5.09% from the prior year.
• Net Income towards Common Stockholders slipped to -$8.2 million in Q2 2026 per STLNW's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$11.1 million across 5 years, with a median of -$13.0 million in 2024.
• The widest YoY moves for Net Income towards Common Stockholders: up 238.35% in 2022, down 673.67% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at -$11.0 million in 2022, then slumped by 70.38% to -$18.8 million in 2023, then soared by 42.27% to -$10.8 million in 2024, then surged by 40.63% to -$6.4 million in 2025, then retreated by 28.22% to -$8.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$8.2 million, -$2.1 million, and -$6.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.